Safety and Efficacy of a 36-Week Induction Regimen of Abacavir/Lamivudine and Ritonavir-Boosted Atazanavir in HIV-Infected Patients-Reference-Cited by-同舟云学术

Safety and Efficacy of a 36-Week Induction Regimen of Abacavir/Lamivudine and Ritonavir-Boosted Atazanavir in HIV-Infected Patients

Published:2010-04 Issue:2 Volume:11 Page:69-79
ISSN:1528-4336
Container-title:HIV Clinical Trials
language:en
Short-container-title:HIV Clinical Trials

Author:

Squires Kathleen E.,Young Benjamin,DeJesus Edwin,Bellos Nicholas,Murphy Daniel,Sutherland-Phillips Denise H.,Zhao Henry H.,Patel Lisa G.,Ross Lisa L.,Wannamaker Paul G.,Shaefer Mark S.,

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Infectious Diseases

Link

http://www.tandfonline.com/doi/pdf/10.1310/hct1102-69

Reference21 articles.

1. Comparisons of Causes of Death and Mortality Rates Among HIV-Infected Persons

2. Decline in the AIDS and death rates in the EuroSIDA study: an observational study

3. Antiretroviral Treatment of Adult HIV Infection

4. Toxicity of antiretroviral therapy and implications for drug development

5. Maintenance Antiretroviral Therapies in HIV-Infected Subjects with Undetectable Plasma HIV RNA after Triple-Drug Therapy

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Role of Pharmacogenomics in Reducing the Risk of Drug-Related Iatrogenesis;Current Pharmacology Reports;2022-01-17

2. Prevalence of human leukocyte antigen HLA-B*57:01 in individuals with HIV in West and Central Africa;BMC Immunology;2021-07-22

3. Drug Resistance Among Adolescents and Young Adults with Virologic Failure of First-Line Antiretroviral Therapy and Response to Second-Line Treatment;AIDS Research and Human Retroviruses;2020-07-01

4. Changes over time in creatinine clearance and comparison of emergent adverse events for HIV-positive adults receiving standard doses (300 mg/day) of lamivudine-containing antiretroviral therapy with baseline creatinine clearance of 30–49 vs ≥50 mL/min;PLOS ONE;2019-11-14

5. Abacavir Hypersensitivity Reaction Reporting Rates During a Decade ofHLA‐B*5701 Screening as a Risk‐Mitigation Measure;Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy;2018-12-11